Literature DB >> 25451050

In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Alexander A Firsov1, Maria V Golikova2, Elena N Strukova2, Yury A Portnoy2, Andrey V Romanov3, Mikhail V Edelstein3, Stephen H Zinner4.   

Abstract

Bacterial resistance studies using in vitro dynamic models are highly dependent on the starting inoculum that might or might not contain spontaneously resistant mutants (RMs). To delineate concentration-resistance relationships with linezolid-exposed Staphylococcus aureus, a mixed inoculum containing both susceptible cells and RMs was used. An RM selected after the 9th passage of the parent strain (MIC, 2 μg/ml) on antibiotic-containing media (RM9; MIC, 8 μg/ml) was chosen for the pharmacodynamic studies, because the mutant prevention concentration (MPC) of linezolid against the parent strain in the presence of RM9 at 10(2) (but not at 10(4)) CFU/ml did not differ from the MPC value determined in the absence of the RMs. Five-day treatments with twice-daily linezolid doses were simulated at concentrations either between the MIC and MPC or above the MPC. S. aureus RMs (resistant to 2× and 4×MIC but not 8× and 16×MIC) were enriched at ratios of the 24-h area under the concentration-time curve (AUC24) to the MIC that provide linezolid concentrations between the MIC and MPC for 100% (AUC24/MIC, 60 h) and 86% (AUC24/MIC, 120 h) of the dosing interval. No such enrichment occurred when linezolid concentrations were above the MIC and below the MPC for a shorter time (37% of the dosing interval; AUC24/MIC, 240 h) or when concentrations were consistently above the MPC (AUC24/MIC, 480 h). These findings obtained using linezolid-susceptible staphylococci supplemented with RMs support the mutant selection window hypothesis. This method provides an option to delineate antibiotic concentration-resistance relationships with bacteria that exhibit low mutation frequencies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25451050      PMCID: PMC4335834          DOI: 10.1128/AAC.04214-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.

Authors:  Silke Besier; Albrecht Ludwig; Johannes Zander; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

2.  Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.

Authors:  M Hentschke; B Saager; M A Horstkotte; S Scherpe; M Wolters; H Kabisch; R Grosse; P Heisig; M Aepfelbacher; H Rohde
Journal:  Infection       Date:  2007-12-28       Impact factor: 3.553

3.  Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.

Authors:  Alexander A Firsov; Yury A Portnoy; Elena N Strukova; Darya S Shlykova; Stephen H Zinner
Journal:  Int J Antimicrob Agents       Date:  2014-07-27       Impact factor: 5.283

4.  Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.

Authors:  Alexander A Firsov; Maria V Smirnova; Irene Yu Lubenko; Sergey N Vostrov; Yury A Portnoy; Stephen H Zinner
Journal:  J Antimicrob Chemother       Date:  2006-10-05       Impact factor: 5.790

5.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

6.  Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.

Authors:  Alexander A Firsov; Irene Y Lubenko; Maria V Smirnova; Elena N Strukova; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

7.  Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.

Authors:  Keith Miller; Alexander J O'Neill; Mark H Wilcox; Eileen Ingham; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

8.  Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.

Authors:  Athanassios Tsakris; Satish K Pillai; Howard S Gold; Claudie Thauvin-Eliopoulos; Lata Venkataraman; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.

Authors:  Stephen H Zinner; Deborah Gilbert; Irene Yu Lubenko; Kenneth Greer; Alexander A Firsov
Journal:  J Antimicrob Chemother       Date:  2008-02-01       Impact factor: 5.790

10.  Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.

Authors:  Keith Miller; Colin J Dunsmore; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

View more
  8 in total

1.  Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Authors:  Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

3.  Linezolid Inhibited Synthesis of ATP in Mitochondria: Based on GC-MS Metabolomics and HPLC Method.

Authors:  Xuemei Ye; Aifang Huang; Xianqin Wang; Congcong Wen; Lufeng Hu; Guanyang Lin
Journal:  Biomed Res Int       Date:  2018-10-16       Impact factor: 3.411

4.  Fluopsin C for Treating Multidrug-Resistant Infections: In vitro Activity Against Clinically Important Strains and in vivo Efficacy Against Carbapenemase-Producing Klebsiella pneumoniae.

Authors:  Miguel Octavio Pérez Navarro; Ane Stefano Simionato; Juan Carlos Bedoya Pérez; André Riedi Barazetti; Janaina Emiliano; Erika Tyemi Goya Niekawa; Matheus Felipe de Lima Andreata; Fluvio Modolon; Mickely Liuti Dealis; Eduardo José de Almeida Araújo; Thalita Massi Carlos; Odair José Scarpelim; Denise Brentan da Silva; Andreas Lazaros Chryssafidis; Per Bruheim; Galdino Andrade
Journal:  Front Microbiol       Date:  2019-10-25       Impact factor: 5.640

5.  Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model.

Authors:  Guang Yang; Yisong Yan; Jun Mao; Huiping Liu; Mingtao Chen; Na Zhang; Yaowen Li; Jiangjun Gu; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2021-12-01       Impact factor: 4.003

6.  Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets?

Authors:  Glenn S Tillotson; Stephen H Zinner
Journal:  EBioMedicine       Date:  2015-06-12       Impact factor: 8.143

7.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

8.  Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?

Authors:  Troy Day; Andrew F Read
Journal:  PLoS Comput Biol       Date:  2016-01-28       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.